5 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 15,311 as of Wednesday, Sept. 25, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,760 issues advancing vs. 1,167 declining with 109 unchanged.

The Health Care sector currently sits up 0.9% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Baxter International ( BAX), down 5.6%, Stryker Corporation ( SYK), down 2.1%, Zimmer Holdings ( ZMH), down 1.3%, WellPoint ( WLP), down 0.9% and Novo Nordisk A/S ( NVO), down 1.0%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.24 (-0.6%) to $38.48 on light volume. Thus far, 1.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $38.16-$38.87 after having opened the day at $38.77 as compared to the previous trading day's close of $38.72.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.1 billion and is part of the drugs industry. Shares are up 1.8% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon